Antibodies represent the gold standard of affinity reagents used for regulated bioanalysis of therapeutic proteins. Over time, traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable. Yet, antibodies and natural ligands have their limitations and can present challenges with supply, stability and batch-to-batch variation on assay performance. This webinar demonstrates a high-performance Affimer assay detecting and quantifying the breast cancer drug Trastuzumab, showing good sensitivity and increased dynamic range compared to the current antibody-based methods.
Topics to be covered:
- How antibody variability impedes pharmacokinetic studies
- What are Affimers, and when to adopt them for your R&D pipeline
Meet the Speakers:
Assay Development Intern